Please assess the completion status of the following clinical trial:

Trial Title: Use of Pyridostigmine for Constipation in Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with diabetes mellitus (Type I or type II), diagnosed by a physician.~* On medical treatment for diabetes (oral medication or injected insulin) for at least one year~* Symptomatic constipation at least 25% of the time in the past year (Rome II criteria for functional constipation)~* 18-70 years of age~* Colonoscopy negative for obstructive lesions, cancer, or inflammatory bowel disease (IBS) within the last 8 years if 50 years of age or older~* Able to provide written informed consent before participating in trial~* Able to communicate adequately with the Investigator and to comply with the requirements for the entire study~Exclusion Criteria:~* History of pelvic floor dysfunction (other functional GI disorders, eg IBS, non-ulcer dyspepsia are acceptable); Specifically, patients will be excluded if they have at least 2 of the following 3 criteria:~  * History of digital evacuation of the rectum or pressure on the posterior aspect of the vagina or perineum to facilitate defecation~ * Examination findings suggestive of puborectalis spasm or anismus, on assessment by an experienced gastroenterologist with expertise in this field; i.e. high anal sphincter tone at rest, failure of perineal descent by \>1cm on straining, and tenderness or paradoxical contraction of the puborectalis on digital examination~ * Requirement of \> 200g to expel a rectal balloon during voluntary straining~* Abdominal surgery other than appendectomy, cholecystectomy, hysterectomy, tubal ligation, or inguinal hernia repair~* Suspected or known gastrointestinal or genitourinary obstruction~* Uncontrolled hypertension (defined as \> 150/90 at rest)~* Known cardiac arrhythmia or ECG abnormalities, i.e. cardiac conduction disturbances (2nd or 3rd degree atrioventricular (AV) block, prolonged corrected QT interval (QTc)(\> 460 msec) or bradycardia (\< 45 beats/minute))~* Renal insufficiency with serum creatinine greater than 2 mg/dl based on a reading from the previous 6 months~* Asthma or chronic obstructive pulmonary disease requiring systemic steroids in the previous 3 years (inhaled steroids acceptable)~* Current use of narcotics, gut prokinetic drugs (eg metoclopramide, domperidone, tegaserod, senekot), anticholinergic medication (eg. Hyoscyamine, belladonna), antidiarrheals (Imodium, Lomotil), or laxatives other than fiber supplements, docusate, or glycerin suppositories. Patients on any of these restricted medications must cease use at least 48 hours before starting and for the duration of both study phases. No rescue laxatives will be permitted within 7 days of transit testing~* Patients who have taken any investigational medications within the past 30 days~* Known intolerance or allergy to eggs~* Pregnant or breast-feeding females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Pyridostigmine (Type: EXPERIMENTAL): Oral pyridostigmine, starting with 60 mg capsules three times per day (TID), increasing by 60 mg every third day (i.e., over 10 days) up to the maximum tolerated dose or 120 mg TID (a total of 360 mg per day). This dose was maintained for 7 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (sham) capsules, matching the appearance of the active drug comparator and taken TID.

Based on this trial design, predict the completion outcome and termination type (if applicable).